NeuroPace (NPCE) Set to Announce Earnings on Tuesday

NeuroPace (NASDAQ:NPCE) will be releasing its earnings data after the market closes on Tuesday, November 12th. Analysts expect NeuroPace to post earnings of ($0.26) per share for the quarter. NeuroPace has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The firm had revenue of $19.26 million during the quarter, compared to analysts’ expectations of $18.30 million. During the same quarter in the prior year, the business earned ($0.36) earnings per share. The company’s revenue was up 16.6% on a year-over-year basis. On average, analysts expect NeuroPace to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NeuroPace Stock Down 0.7 %

NPCE opened at $7.51 on Friday. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97. The stock has a market capitalization of $219.29 million, a price-to-earnings ratio of -6.89 and a beta of 1.79. The business has a 50 day moving average of $6.82 and a 200-day moving average of $7.61.

Insider Transactions at NeuroPace

In related news, major shareholder Ltd. Kck sold 4,031 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74. Following the transaction, the insider now directly owns 5,521,874 shares of the company’s stock, valued at approximately $36,113,055.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 257,590 shares of company stock worth $1,437,916 in the last 90 days. Corporate insiders own 22.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price objective on shares of NeuroPace in a research note on Wednesday, August 14th. Morgan Stanley dropped their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Finally, Wells Fargo & Company decreased their target price on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.00.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.